New Phase

Company Overview

Snapshot

Founded in August 2013 by Ofer Shalev and Rafael Hof, New Phase operates with 11–50 employees. The company has raised $35 million across three funding rounds. In June 2024, New Phase received FDA approval for clinical trials in the U.S., marking a significant step towards expanding its innovative cancer treatment technology.

Business overview

New Phase is an oncology company developing breakthrough solutions for metastatic solid tumors. Its core technology involves a Nanotechnology System that delivers thermal energy to malignant cells via electromagnetic hyperthermia, aiming to cause cancer cell death without harming healthy tissues. The system utilizes proprietary Sarah Nanoparticles (SaNPs) administered intravenously, which are then activated by an Electromagnetic Induction System (EIS) to heat cancer cells to 50°C. This approach is designed to be a standalone treatment for stage IV patients, transforming cancer into a manageable chronic disease. New Phase operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving the healthcare and pharmaceutical industries.

Strategic signal

In June 2024, New Phase secured FDA approval to commence clinical trials in the U.S. for its groundbreaking cancer treatment. This regulatory milestone is a critical validation of the company's nanotechnology system, signaling its potential to enter a major market and accelerate the development of its therapeutic hyperthermia technology for metastatic solid tumors. For investors, this indicates significant progress in de-risking the technology and expanding its commercial pathway, positioning New Phase for potential future growth and broader patient impact.

Company Intelligence Q&A

What is New Phase's core technology for cancer treatment?

New Phase utilizes a Nanotechnology System that employs Sarah Nanoparticles (SaNPs) and an Electromagnetic Induction System (EIS). SaNPs are administered intravenously and accumulate in cancer cells, then activated by the EIS to generate thermal energy, destroying malignant cells without harming healthy tissue.

What significant regulatory milestone did New Phase achieve in 2024?

In June 2024, New Phase received FDA approval to initiate clinical trials in the U.S. for its innovative cancer treatment. This approval marks a key step in advancing its therapeutic hyperthermia technology.

What is the total capital raised by New Phase?

New Phase has raised a total of $35 million across three funding rounds to advance its therapeutic hyperthermia technology for oncology.

What was a key development for New Phase in January 2023?

In January 2023, New Phase received a grant from the BIRD Foundation, supporting the development of its nanotechnology system for cancer treatment.

What is the strategic aim of New Phase's treatment approach?

New Phase aims to transform metastatic solid tumors into a manageable chronic disease. Its technology is designed to be a standalone treatment for stage IV patients, offering an alternative approach to prolong life without severe side effects.